As of Aug 26
| +0.60 / +1.23%|
The 8 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 65.50, with a high estimate of 96.00 and a low estimate of 60.00. The median estimate represents a +32.22% increase from the last price of 49.54.
The current consensus among 9 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.